Mochtar Riady Institute For Nanotechnology

What Mochtar Riady Institute For Nanotechnology does

Mochtar Riady Institute for Nanotechnology (MRIN) is a private cancer and molecular biology research institution headquartered in Lippo Karawaci, Tangerang, Banten, Indonesia, operating as part of the Universitas Pelita Harapan (UPH) Medical Science Group and affiliated with the Siloam Hospitals network. Founded by Lippo Group chairman Mochtar Riady and recognized as Indonesia's first private cancer research institution, MRIN conducts genomic and proteomic research focused on cancer (including hepatitis B/C-related liver cancer, immune response biomarkers, and SNP-based cancer susceptibility), population genetics (the Indonesia Genome Diversity Project covering 1,000+ communities), paleogenomics, and infectious disease surveillance. The institute also operates MRIN-ACRO, a contract research organization providing pre-clinical in-vitro and in-vivo testing services — including barrier-maintained SPF rodent studies for cancer and diabetes research — and an ethics committee providing accredited human and animal subject review.

Revenue is generated through multiple streams: (1) MRIN-ACRO contract research services to pharmaceutical, biotech, academic, and healthcare clients; (2) ISO/IEC 17025:2017-accredited laboratory testing (Sanger sequencing for human/animal/bacterial/viral DNA, and rodent hematology via flow cytometry); (3) competitive international research grants from bodies including the Academy of Medical Sciences UK, Wellcome Trust, European Research Council, National Science Foundation, and Shanghai Municipal Science and Technology Commission; and (4) collaborative research partnerships with international institutions such as NCGM Japan, University of Oxford, University of Cambridge, Variant Bio, Kyoto University, and Tongji Hospital. The institute holds ISO/IEC 17025:2017 accreditation (LP-2250-IDN) valid through April 2031, is a member of the ARISE alliance for ASEAN clinical research and the WHO's International Pathogen Surveillance Network (since March 2025), and houses a separate commercial subsidiary, MDI (MRIN Diagnostic Indonesia), for in-vitro diagnostic kit development. The institute operates with a lean team of approximately 30 employees under President Prof. Irawan Yusuf and Executive Director Dr. Juandy Jo.

Name

Mochtar Riady Institute For Nanotechnology

Legal name

Mochtar Riady Institute for Nanotechnology

Website

https://mrinstitute.org

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Mochtar Riady Institute for Nanotechnology (MRIN) is Indonesia's first private cancer research institution, conducting genomic and proteomic research on cancer, population genetics, and infectious diseases while operating a contract research organization (MRIN-ACRO) providing accredited preclinical laboratory services to pharma, biotech, and academic clients across ASEAN.

Ownership category

akta.pro rank

Product category

Contract Research and Biomedical Laboratory Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Cancer research services
• Contract research organization
• Genomic proteomic analysis
• Preclinical animal studies
• Population genetics research

Headquarters

HQ city

Tangerang

HQ country

Indonesia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Contract Research Services (MRIN-ACRO): Provides translational studies, pre-clinical feasibility, efficacy, safety and regulatory-based tests to meet national and international standards. Services are tailored to client's research and testing purposes.
2. Laboratory Testing Services: Accredited testing services including Sanger sequencing for DNA samples and hematology rodent testing under ISO/IEC 17025:2017 standards.
3. Research Grants: International research grants from organizations such as The Academy of Medical Sciences UK (£24,905.33 for gonorrhea surveillance), Wellcome Trust (Punan Batu research), European Research Council (ERC), and National Science Foundation.
4. Collaborative Research Projects: Joint AI-driven cancer research with Tongji Hospital funded by Shanghai Municipal Science and Technology Commission (RMB 400,000 grant)

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

MRIN is a private biomedical research institute focused on cancer research using genomic and proteomic approaches, including hepatitis B and C virus genotype studies, immune response biomarker analysis, and SNP microarray for cancer susceptibility loci. It operates MRIN-ACRO as a contract research organization providing in-vitro and in-vivo preclinical testing, Sanger sequencing, hematology rodent testing, and SPF barrier animal facility services to pharmaceutical, biotech, and academic clients.

Product overview

MRIN operates as a research institute offering a comprehensive portfolio of products and services centered on cancer research and molecular diagnostics. The core offering consists of MRIN Research Services focused on cancer, genomics, and proteomics. MRIN-ACRO extends these capabilities as a Contract Research Organization providing preclinical testing services (in-vitro and in-vivo), while specialized divisions handle IVD kit development (dengue, HCG, Salmonella Typhi tests). The laboratory services are supported by ISO/IEC 17025:2017 accreditation covering Sanger sequencing and rodent hematology. MDI (MRIN Diagnostic Indonesia) serves as the diagnostic products subsidiary. The institute also provides animal research facilities including quarantine services and preclinical animal studies for cancer and diabetic research.

Differentiator

Problem solved

Functional benefit

Brands

• MRIN-ACRO: Contract Research Organization providing translational studies, pre-clinical, feasibility, efficacy, safety, and regulatory-based testing services

Products and services

• MRIN Research Services Core cancer research services using genomic and proteomic approaches, including hepatitis B and C virus genotype and mutation studies, immune response biomarker analysis for immunotherapy, and SNP microarray for identifying cancer susceptibility loci in Indonesian patient populations.
• MRIN-ACRO Contract Research Organization Services Contract research organization providing translational studies, pre-clinical feasibility, efficacy, safety, and regulatory-based tests to pharmaceutical companies, biotech firms, and research institutions. Includes in-vitro and in-vivo testing supported by a barrier animal facility for SPF rodent models with comprehensive sample collection for blood chemistry, hematology, and molecular marker assessments.
• Sanger Sequencing Services DNA nucleotide sequencing service for human, animal, bacterial, and viral DNA samples. Accredited under ISO/IEC 17025:2017 by KAN (Komite Akreditasi Nasional), accreditation number LP-2250-IDN, valid from April 22, 2026 to April 21, 2031.
• Rodent Hematology Testing Hematology testing for rats and mice using flow cytometry, including RBC, WBC, platelet, and reticulocyte counts. Accredited under ISO/IEC 17025:2017.
• Animal Quarantine Services Animal quarantine facilities for imported specific pathogen-free (SPF) laboratory animals, including husbandry and animal care services for institutions conducting research requiring imported animals.
• Preclinical Animal Studies Animal model services for cancer and diabetic studies with comprehensive sample collection, blood chemistry, hematology, molecular markers, and anatomical, histological, and molecular pathology assessments.
• COVID-19 Diagnostic Services COVID-19 diagnostic testing services provided in collaboration with Siloam Hospitals during the pandemic outbreak, supporting clinical research and testing capabilities.
• IVD Kit Development In-vitro diagnostic kit development services including dengue, HCG, and Salmonella Typhi IgM/IgG rapid test kit development.
• MDI - MRIN Diagnostic Indonesia Diagnostic products subsidiary developing and providing in-vitro diagnostic kits.

Quantifiable outcome

• ISO/IEC 17025:2017 accreditation (LP-2250-IDN) valid until April 21, 2031
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

24 partnerships are on record, tiered flagship, core and minor.

• Tongji Hospital (Tongji University, Shanghai)flagshipStrategic or Co-development Partner · 15 May 2026AI-driven cancer research partnership focused on early detection of liver metastasis in colorectal cancer. Memorandum of cooperation signed May 15, 2026. Project: 'Construction and Clinical Translation of Multimodal AI-based Early Prediction Model for Postoperative Liver Metastasis in Colorectal Cancer.' Grant: RMB 400,000 (~IDR 1 billion) from Shanghai Municipal Science and Technology Commission. Duration: 2 years. Activities at Tongji Hospital and East China Normal University. Principal Investigator: Ariela Samantha PhD from MRIN.
• ARISE (Academic Research Organization Alliance for ASEAN and East Asia)flagshipStrategic or Co-development Partner · 16 October 2025MRIN is one of two Indonesian institutions (alongside Universitas Indonesia) in this alliance of six medical research institutes from three ASEAN countries. ARISE aims to promote multi-regional clinical trials in ASEAN and East Asia, resolving complexity from regulatory and ethical differences, medical systems, and ethnic diversity.
• University of OxfordcoreStrategic or Co-development Partner · 31 March 2025Collaboration partner in INDIGO project (International Network Development in Indonesia for Gonorrhoea Surveillance). Awarded 2025 Academy of Medical Sciences Networking Grant (£24,905.33). Also involves collaboration with Kyushu University Center for Clinical and Translational Research.
• BRIN (National Research and Innovation Agency) - Archaeological, Language, and Literature Research OrganizationcoreStrategic or Co-development Partner · 2 August 2022MoU signed August 2, 2022 for archaeology and paleogenomics scientific research. Collaborative research focusing on paleogenomics analysis from prehistoric human in Indonesia. Activities include ancient DNA analysis on findings of prehistoric human teeth and skeletons in Sulawesi and Papua. Includes capacity building seminars and workshops.
• Variant BiocoreStrategic or Co-development Partner · 20 April 2022Biotechnology company (Seattle, USA) collaboration for Indonesian population genome diversity studies. Partnership to study local genetic variants related to diseases. Includes community-based participatory research approach. Seminar 'Connecting the Dots Between Academics and Industry: From Genomics to Precision Medicine' held November 1, 2022.
• National Center for Global Health and Medicine (NCGM) JapanflagshipStrategic or Co-development Partner · 9 December 2021MoU signed December 9, 2021 for cooperation in preparing for future global health problems. Bridges Multi-Regional Clinical Trial (MRCT) network organized by NCGM with ARISE. MRIN President Prof. Irawan Yusuf, Executive Director Dr. Juandy Jo, and PI Dr. Ivet Suriapranata attended signing. Collaboration includes NCGM study monitoring visits and clinical research capacity building.
• Universitas IndonesiacoreStrategic or Co-development Partner · 23 June 2021Indonesia's other ARISE alliance member alongside MRIN. Together representing Indonesia in the multi-regional clinical trial network.
• East China Normal UniversitycoreStrategic or Co-development PartnerCollaborating institution in the AI-driven colorectal cancer research project alongside Tongji Hospital. Supervised by Prof. Wang Yan PhD for project activities.
• Pusat Riset Biologi Molekular Eijkman - BRINcoreStrategic or Co-development PartnerPartner in INDIGO gonorrhea surveillance project. BRIN is National Research and Innovation Agency, involved in infectious disease research collaboration.
• Universitas Jenderal SoedirmanminorStrategic or Co-development PartnerPartner in INDIGO gonorrhea surveillance project for building surveillance network in Indonesia.
• Rumah Sakit Penyakit Infeksi Sulianti SarosominorStrategic or Co-development PartnerPartner in INDIGO gonorrhea surveillance project for infectious disease surveillance network.
• University of CambridgecoreStrategic or Co-development PartnerResearch collaboration on Indonesian population genome diversity. Dr. Guy Jacobs from Cambridge participated in seminars and research on Indonesian Genome Diversity Project (IGDP) and Punan communities in Borneo. Collaboration includes European Research Council (ERC) funded MOBILE project.
• Santa Fe InstitutecoreStrategic or Co-development PartnerCollaboration with Prof. Steve Lansing on Punan Batu hunter-gatherer community research in Borneo. Studies genomics and behavioral ecology of nomadic communities. Funded by National Science Foundation and European Research Council.
• Australian Centre for Ancient DNA (ACAD), The University of AdelaidecoreStrategic or Co-development PartnerCollaboration partner in paleogenomics capacity building for Indonesian researchers and archaeologists. Assoc. Prof. Bastien Llamas conducted paleogenomics workshop following MRIN-BRIN MoU signing. Two-day capacity building event on ancient DNA analysis techniques.
• Kyoto University - Graduate School of Asian and African Area StudiescoreStrategic or Co-development PartnerMRIN participated in Maritime Asian and Pacific Studies international symposium January 26-28, 2024. Prof. Irawan Yusuf presented disease burden research in Wallacea region. Continued collaboration in health research.
• Kyushu University - Center for Clinical and Translational ResearchcoreStrategic or Co-development PartnerJapan collaboration institution following 2nd ARISE Annual Meeting. Visit planned for February 2024 to discuss and set up Indonesia-Japan clinical research collaboration.
• Siloam Hospitals GroupflagshipStrategic or Co-development PartnerCOVID-19 diagnostic collaboration since pandemic outbreak. MRIN part of UPH Medical Science Group serving as unique hub for bench-to-bedside translational studies. Siloam Hospital Lippo Village used as recruitment site for clinical studies.
• Eijkman Institute for Molecular BiologycoreStrategic or Co-development PartnerIndonesian institution collaboration. Eijkman Institute is prominent molecular biology research center in Indonesia. MRIN researchers have history of collaboration including previous work at Eijkman before MRIN establishment.
• PT. IPB-ShigetaminorStrategic or Co-development PartnerIndonesian animal pharmaceuticals vaccine manufacturer collaboration.
• University New South Wales (UNSW Sydney)minorStrategic or Co-development PartnerInternational institutional collaboration with Australian university.
• Health Security PartnersminorStrategic or Co-development PartnerNonprofit international development organization collaboration on SARS-CoV-2 surveillance at human-animal-environment interface. Project collaboration with BRIN, IPB University Primate Research Center, Warmadewa University, and local health offices.
• Pusat Riset Arkeologi Prasejarah dan Sejarah - BRINcoreStrategic or Co-development PartnerCollaboration on SARS-CoV-2 and zoonotic virus surveillance research in areas with wild bat circulation. Part of One Health approach to disease monitoring.
• Primate Research Center at IPB UniversityminorStrategic or Co-development PartnerPartner in One Health surveillance project for SARS-CoV-2 and zoonotic viruses at human-animal interface.
• Warmadewa UniversityminorStrategic or Co-development PartnerPartner in One Health surveillance collaboration for pathogen research.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• WuXi AppTec: Asia's largest CRO/CDMO with comprehensive preclinical, genomic, and clinical trial capabilities. Competes with MRIN for Asian pharma/biotech CRO contracts and represents the dominant scaled peer MRIN must position against in ASEAN.
• IQVIA: Global clinical research and contract research services leader with deep Asia-Pacific presence. Directly comparable to MRIN's clinical trial support ambitions through the ARISE alliance, though operating at global scale.
• Eurofins Scientific: Global laboratory testing services group with extensive genomic, molecular diagnostics, and clinical trial central lab capabilities. Comparable to MRIN's accredited Sanger sequencing and hematology testing services but at vastly greater global scale.
• Labcorp: Global clinical diagnostics and early development CRO with central laboratory and preclinical services. Comparable to MRIN's clinical diagnostics and trial-support capabilities at vastly greater scale and geographic reach.
• Charles River Laboratories: Global CRO providing preclinical services including animal models, hematology, and safety/efficacy testing — directly overlapping with MRIN-ACRO's preclinical CRO offering. Charles River is the incumbent MRIN-ACRO must differentiate against on scale and international client reach.

Direct peers

• Macrogen: Asia-headquartered genomic services company providing Sanger sequencing, NGS, and molecular diagnostics for research and clinical clients. Closest direct peer to MRIN's accredited genomic laboratory services in terms of service portfolio and regional positioning.
• deCODE genetics (Amgen): Population genomics company specializing in large-scale human genetic variation studies for disease discovery. Closest peer to MRIN's Indonesia Genome Diversity Project in population-scale human genomics methodology and disease-variant discovery.
• Eijkman Institute / BRIN Molecular Biology: Indonesia's premier molecular biology and pathogen genomics research institution, now part of BRIN. MRIN has a documented collaboration history with Eijkman and competes for the same national mandate in infectious disease genomics, pathogen surveillance, and population genetics research.

Regional players

• Sysmex: Japan-based leader in hematology and clinical diagnostics instrumentation, including flow cytometry platforms. Relevant peer for MRIN's accredited rodent hematology testing services and clinical pathology workflow.
• Genome Institute of Singapore (A*STAR GIS): Singapore's flagship genomics and population genetics research institute under A*STAR. Operates in adjacent Southeast Asian population genomics and precision medicine space, sharing disease-genetics research priorities with MRIN's Indonesian Genome Diversity Project.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mochtar-riady-institute-for-nanotechnology

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mochtar Riady Institute For Nanotechnology